Fundz

Eumentis Therapeutics reported raising $4 Million in an initial SEC Form D filing, from an offering of $20 Million

PRIVATEMar 17, 2023$4M of $20M raised

Amount Raised

$4 Million

$4 Million sold, per SEC Form D (first sale Mar 17, 2023)

Round Type

Seed

NewtonHealthcare

Who else raised in Healthcare around the same time

Companies in the same sectors as Eumentis Therapeutics, Inc. that raised within 45 days of this round, from Fundz verified event records.

  • Novabay raised $3M (Seed) on May 1, 2023.
  • Reperio Health raised $2M (Seed) on May 1, 2023.
  • Eledon raised $185M (Funding Round) on May 1, 2023.
  • TFF Pharmaceuticals, Inc. raised an undisclosed amount (Funding Round) on May 1, 2023.
  • Headlands Research raised $1.4M (Seed) on May 1, 2023.
  • POLLIE, INC. raised $120K (Seed) on May 1, 2023.

Who to call at Eumentis Therapeutics, Inc., and when

A new round usually means Eumentis Therapeutics, Inc. is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Eumentis Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Eumentis Therapeutics, Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Eumentis Therapeutics, Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Eumentis Therapeutics, Inc.

Location

508 DUDLEY ROAD

Newton, Massachusetts, United States

About

EuMentis Therapeutics Inc. is a privately held clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat neuropsychiatric conditions with high unmet need. The Company’s most advanced product candidate, EM-221, is a best-in-class oral PDE10A inhibitor designed to modulate the dopamine D2 pathway specifically in the striatum. EuMentis plans to initiate a phase 2 study of EM-221 for the treatment of Tourette Syndrome in H2 2023. EuMentis is also developing EM-113, an uncompetitive fast-off NMDA receptor antagonist for the treatment of Autism Spectrum Disorder patients with elevated brain glutamate levels as determined by MR spectroscopy. EuMentis is also expanding its pipeline through the development of extrasynaptic NMDAR antagonists for treatment of multiple conditions in which elevated glutamate levels contribute to the pathophysiology including Traumatic Brain Injury (TBI), at present funded by an award from the United States Department of Defense. EuMentis was founded in 2019 with the mission to develop novel therapies to improve the quality of life of patients suffering from central nervous system (“CNS”) disorders.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Eumentis Therapeutics, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsRandall M., Executive Officer hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Eumentis Therapeutics, Inc.'s next move

See what Strategic adds

Eumentis Therapeutics, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.